Opinion|Videos|July 29, 2024
How Experts View MAIC Data That was Presented at EHA 2024
A panel of experts examines and interprets the most recent matching-adjusted indirect comparison (MAIC) data presented at the European Hematology Association 2024 conference, focusing on the comparative analysis of the ASCEND and ALPINE trials in chronic lymphocytic leukemia treatment.
Advertisement
Episodes in this series
- Briefly discuss key data from the latest MAIC data presented at EHA 2024:
- MAIC: ASCEND vs ALPINE –
Shadman, et al. EHA 2024. Abstract P700 - How do these data compare to those previously reportedcomparing ASCEND and ALPINE data? (
Kittai A, et al. ASCO 2023. Abstract 7540 )
- How do these data compare to those previously reportedcomparing ASCEND and ALPINE data? (
- MAIC: ASCEND vs ALPINE –
- How do you interpret these findings and other available MAIC data and what further insights do they provide?
- What guidance can you offer community oncologists about incorporating MAIC data in treatment decisions?
Advertisement
Related to this article
The top 5 OncLive TV videos of the week cover pancreatic cancer, gastric cancer, GIST, renal cell carcinoma, and chronic lymphocytic leukemia.
Advertisement
Advertisement
Trending on OncLive
1
Five Under 5: Top Oncology Videos for the Week of 8/31/26
2
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
3
B7-H4–Targeted ADCs Signal a New Frontier for Platinum-Resistant Ovarian and Endometrial Cancer
4
The OncFive: Top Oncology Articles for the Week of 8/30
5